compared with the first, whereas the prolactin response was unaltered. We now report the endocrine effects of repeated intravenous infusions of RX77368 in MND.Seven patients (six male, one female, age range 43-67) with MND' were given six intravenous infusions of'RX77368 on Mondays and Thursdays of three successive weeks, starting at 9.30 am on each occasion. The dose of RX77368 was 0-2 mg/kg, given over two hours. If side effects were unaccep- before, after one hour and at the end of the infusion, then at four and six hours after the infusion, and every morning at 9 am until the next infusion. All hormones were measured as previously described,' except that prolactin standards were obtained from the Division ofMolecular Endocrinology, Hammersmith Hospital, London. The detection limit for prolactin was 40 mU/l. Results were analysed using analysis of variance with Duncan's test for multiple comparisons. Correlations between groups were described using Spearman's test. The study was approved by the local ethics committee. Each time point has been ascribed a number in the order in which blood samples were taken, and is identified by this number in the graphs (fig). Samples were taken during and immediately after the infusions more rapidly than at other times, and thus the time scale of the points in the graph is not constant.The not, however, influence the effect ofRX77368 on the release of prolactin, further evidence that the TRH stimulated post receptor events in lactotrophs and thyrotrophs are differentially regulated. If RX77368 was administed on the present dose schedule over extended periods of time, thyrotoxicosis should not be a significant side effect. The baseline thyroid function would not alter, though there would be periods during and immediately after infusions when the peripheral thyroid hormones would be significantly elevated. The possibility thus exists of using RX77368 in such a way as to avoid the hazard of thyrotoxicosis.

Fibrous hamartoma of infancy (FHI) is a benign, poorly demarcated, unencapsulated hamartoma contiguous with surrounding fat. This case highlights pronounced bony remodeling and muscle atrophy associated with FHI in a 6‐week‐old girl. Emphasis is placed on pathologic diagnosis and mechanisms, treatment considerations, and the multidisciplinary approach utilized in the management of the disorder.